stockrow
Saturday 7 November 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
- Revenue
- +37,272.4%
- EPS
- +85.0%
- Free cash flow
- −0.52%
- Total debt
- +0.22%
Quarter to September 2026, against a year earlier
10.60
0.73
+7.40%
Follow DTIL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 3.01 | 1.56 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (11.35) | (4.74) | |
P/B ratio |
— | — | 1.78 | 0.58 | |
Price to Tangible BV |
— | — | 1.81 | 0.59 | |
EV/Sales |
— | — | 1.26 | (1.16) | |
EV/EBITDA |
— | — | 0.00 | 0.80 | |
EV/Operating CF |
— | — | (0.97) | 0.60 | |
EV/FCF |
— | — | (0.96) | 0.60 | |
Quick Ratio |
9.90 | 12.26 | 13.56 | 12.97 | |
Current Ratio |
10.47 | 12.82 | 14.02 | 13.32 | |
Net Debt/EBITDA |
2.99 | 3.51 | 9.34 | (7.07) | |
Debt/Assets |
18.63% | 17.81% | 15.58% | 14.51% | |
Debt/Equity |
0.43 | 0.50 | 0.29 | 0.24 | |
Asset Turnover |
0.00 | 0.00 | 0.34 | 0.24 | |
Operating CF/Net income |
1.99 | 0.41 | 0.65 | (0.56) | |
Capex/Depreciation |
(0.34) | 0.00 | (0.18) | (0.48) | |
Interest Coverage |
(66.54) | (63.87) | (29.18) | 35.94 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 120.96% | 42.29% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 62.77% | 21.14% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 14.29% | 5.97% | |
Graham Net Nets |
— | — | 0.30 | 1.06 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (66.55%) | (123.08%) | |
Free Cash Flow Yield |
— | — | (43.67%) | (124.59%) | |
Revenue per Share |
0.00 | 0.00 | 0.44 | 2.67 | |
Operating CF per Share |
(0.55) | (0.52) | (0.48) | (0.88) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.03) | |
Free Cash Flow per Share |
(0.56) | (0.52) | (0.49) | (0.90) | |
Cash per Share |
2.98 | 3.39 | 4.11 | 9.01 | |
Shareholders Equity per Share |
1.89 | 1.75 | 3.09 | 7.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.89 | 1.75 | 3.09 | 7.19 | |
Free Cash Flow |
(15.33) | (13.44) | (12.05) | (11.57) | |
Working Capital |
78.31 | 84.41 | 100.94 | 109.83 | |
Capital Expenditures |
(0.20) | 0.00 | (0.11) | (0.32) | |
Net Current Asset Value |
17.97 | 10.92 | 40.90 | 56.57 | |
EV/EBIT |
— | — | 0.00 | 0.76 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 2.09 | — | |
Average Payables |
1.08 | 0.97 | 0.93 | 0.80 | |
Average Assets |
106.94 | 117.42 | 134.15 | 145.40 | |
Average Common Equity |
34.20 | 39.67 | 62.72 | 74.32 |
Columns are period end dates · fundamentals updated 5 Nov 2026